AXDX - アクセレレ―ト・ダイアグノスティックス (Accelerate Diagnostics Inc.)

AXDXのニュース

   Accelerate Diagnostics Inc. (NASDAQ: AXDX) Rose 4.26% From Its 52-Week Low; YTD Numbers Fall -72.99% – Here Are Some Things To Keep In Mind  2022/04/02 13:30:00 Marketing Sentinel
During the last session, Accelerate Diagnostics Inc. (NASDAQ:AXDX)’s traded shares were 0.81 million, with the beta value of the company hitting 1.82. At the end of the trading day, the stock’s price was $1.41, reflecting an intraday loss of -2.08% or -$0.03. The 52-week high for the AXDX share is $9.42, that puts it down … Accelerate Diagnostics Inc. (NASDAQ: AXDX) Rose 4.26% From Its 52-Week Low; YTD Numbers Fall -72.99% – Here Are Some Things To Keep In Mind Read More »
   Accelerate Diagnostics launches Accelerate Arc system for use in blood culture test  2022/03/28 14:50:12 Seeking Alpha
Accelerate Diagnostics (AXDX) launched its blood culture testing product Accelerate Arc system, that comprises of the Arc Module and BC Kit. The product is designed for labs and is a…
   Is Accelerate Diagnostics Inc. (NASDAQ: AXDX) Still A Buy After sinking -23.50% Last Week?  2022/03/12 12:30:00 Marketing Sentinel
During the last session, Accelerate Diagnostics Inc. (NASDAQ:AXDX)’s traded shares were 0.42 million, with the beta value of the company hitting 1.91. At the end of the trading day, the stock’s price was $1.79, reflecting an intraday loss of -5.29% or -$0.1. The 52-week high for the AXDX share is $9.79, that puts it down … Is Accelerate Diagnostics Inc. (NASDAQ: AXDX) Still A Buy After sinking -23.50% Last Week? Read More »
   Accelerate Diagnostics'' (AXDX) CEO Jack Phillips on Q4 2021 Results - Earnings Call Transcript  2022/03/09 02:29:05 Seeking Alpha
   Accelerate Diagnostics reports Q4 results (NASDAQ:AXDX)  2022/03/08 21:34:22 Seeking Alpha
Accelerate Diagnostics press release (AXDX): Q4 GAAP EPS of -$0.34.Revenue of $3.3M (+6.5% Y/Y).
   Accelerate Diagnostics Inc. (NASDAQ: AXDX) Rose 4.26% From Its 52-Week Low; YTD Numbers Fall -72.99% – Here Are Some Things To Keep In Mind  2022/04/02 13:30:00 Marketing Sentinel
During the last session, Accelerate Diagnostics Inc. (NASDAQ:AXDX)’s traded shares were 0.81 million, with the beta value of the company hitting 1.82. At the end of the trading day, the stock’s price was $1.41, reflecting an intraday loss of -2.08% or -$0.03. The 52-week high for the AXDX share is $9.42, that puts it down … Accelerate Diagnostics Inc. (NASDAQ: AXDX) Rose 4.26% From Its 52-Week Low; YTD Numbers Fall -72.99% – Here Are Some Things To Keep In Mind Read More »
   Accelerate Diagnostics launches Accelerate Arc system for use in blood culture test  2022/03/28 14:50:12 Seeking Alpha
Accelerate Diagnostics (AXDX) launched its blood culture testing product Accelerate Arc system, that comprises of the Arc Module and BC Kit. The product is designed for labs and is a…
   Is Accelerate Diagnostics Inc. (NASDAQ: AXDX) Still A Buy After sinking -23.50% Last Week?  2022/03/12 12:30:00 Marketing Sentinel
During the last session, Accelerate Diagnostics Inc. (NASDAQ:AXDX)’s traded shares were 0.42 million, with the beta value of the company hitting 1.91. At the end of the trading day, the stock’s price was $1.79, reflecting an intraday loss of -5.29% or -$0.1. The 52-week high for the AXDX share is $9.79, that puts it down … Is Accelerate Diagnostics Inc. (NASDAQ: AXDX) Still A Buy After sinking -23.50% Last Week? Read More »
   Accelerate Diagnostics'' (AXDX) CEO Jack Phillips on Q4 2021 Results - Earnings Call Transcript  2022/03/09 02:29:05 Seeking Alpha
   Accelerate Diagnostics reports Q4 results (NASDAQ:AXDX)  2022/03/08 21:34:22 Seeking Alpha
Accelerate Diagnostics press release (AXDX): Q4 GAAP EPS of -$0.34.Revenue of $3.3M (+6.5% Y/Y).
   Accelerate Diagnostics slips 3% as prelim 4Q FY21 revenue expected to be below consensus  2022/01/13 14:29:31 Seeking Alpha
Accelerate Diagnostics (AXDX) slips 3% as 4Q revenue is expected to be ~$3.3M (consensus $3.75M) compared to $3.1M in 4Q20.FY21 revenue is expected to be $11.8M (consensus…
   Accelerate Diagnostics (NASDAQ:AXDX) Upgraded to Hold at Zacks Investment Research  2021/12/15 23:04:41 Dakota Financial News
Accelerate Diagnostics (NASDAQ:AXDX) was upgraded by Zacks Investment Research from a sell rating to a hold rating in a report released on Wednesday, Zacks.com reports. According to Zacks, Accelerate Diagnostics, Inc. is focused on developing and commercializing instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The company is developing BACcel(TM) system, []
   Contrasting Nautilus Biotechnology (NASDAQ:NAUT) and Accelerate Diagnostics (NASDAQ:AXDX)  2021/12/13 09:00:43 ETF Daily News
Nautilus Biotechnology (NASDAQ:NAUT) and Accelerate Diagnostics (NASDAQ:AXDX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, valuation, earnings and institutional ownership. Institutional & Insider Ownership 71.3% of Nautilus Biotechnology shares are held by institutional investors. Comparatively, [] The post Contrasting Nautilus Biotechnology (NASDAQ:NAUT) and Accelerate Diagnostics (NASDAQ:AXDX) appeared first on ETF Daily News .
   Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Shares Acquired by Goldman Sachs Group Inc.  2021/12/08 09:06:46 Dakota Financial News
Goldman Sachs Group Inc. grew its position in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) by 49.2% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 48,526 shares of the medical research companys stock after purchasing an additional 16,005 shares during the period. Goldman Sachs Group Inc. owned approximately []
   Accelerate Diagnostics Inc.s (AXDX) -0.80% Retreat Justifies A Second Look  2021/12/04 16:30:00 Stocks Register
Accelerate Diagnostics Inc. (NASDAQ:AXDX) concluded the trading at $4.97 on Friday, December 03 with a fall of -0.80% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $5.01 and 5Y monthly beta was reading 1.88 with its price kept floating in the Accelerate Diagnostics Inc.s (AXDX) -0.80% Retreat Justifies A Second Look Read More »

calendar